KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Co-Diagnostics (CODX) Debt to Equity (2017 - 2021)

Historic Debt to Equity for Co-Diagnostics (CODX) over the last 5 years, with Q3 2021 value amounting to $0.0.

  • Co-Diagnostics' Debt to Equity fell 8243.58% to $0.0 in Q3 2021 from the same period last year, while for Sep 2021 it was $0.0, marking a year-over-year decrease of 8243.58%. This contributed to the annual value of $0.0 for FY2020, which is 9855.29% down from last year.
  • Co-Diagnostics' Debt to Equity amounted to $0.0 in Q3 2021, which was down 8243.58% from $0.0 recorded in Q2 2021.
  • Co-Diagnostics' Debt to Equity's 5-year high stood at $4.0 during Q3 2018, with a 5-year trough of -$0.36 in Q4 2018.
  • For the 5-year period, Co-Diagnostics' Debt to Equity averaged around $0.27, with its median value being $0.05 (2020).
  • Within the past 5 years, the most significant YoY rise in Co-Diagnostics' Debt to Equity was 360017.16% (2018), while the steepest drop was 33032.11% (2018).
  • Over the past 5 years, Co-Diagnostics' Debt to Equity (Quarter) stood at $0.16 in 2017, then plummeted by 330.32% to -$0.36 in 2018, then soared by 143.3% to $0.16 in 2019, then crashed by 98.55% to $0.0 in 2020, then tumbled by 73.36% to $0.0 in 2021.
  • Its Debt to Equity was $0.0 in Q3 2021, compared to $0.0 in Q2 2021 and $0.0 in Q1 2021.